Iguratimod clinical trials
Iguratimod is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Peking Union Medical College Hospital (1). The most-studied condition is Autoimmune Diseases.
How Iguratimod works
All drug targets →- Macrophage migration inhibitory factor inhibitor InhibitorTarget: MIF macrophage migration inhibitory factorChEMBL only
- E3 ubiquitin ligase TRAF3IP2 inhibitor InhibitorTarget: TRAF3IP2 TRAF3 interacting protein 2ChEMBL only
- Cyclooxygenase-2 inhibitor InhibitorTarget: PTGS2 prostaglandin-endoperoxide synthase 2ChEMBL only
- Chronic graft versus host diseasePhase 3
- Osteoarthritis, handPhase 2/3
- Autoimmune thrombocytopenic purpuraPhase 2
- Lupus nephritisPhase 2
- Sjogren syndromePhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2107455, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9736, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Iguratimod
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Iguratimod
- ChEMBL
- CHEMBL2107455
- DrugBank
- DB12233
- PubChem CID
- 124246
- CAS number
- 123663-49-0
- FDA UNII
- 4IHY34Y2NV
- Wikidata
- Q13575264
- Wikipedia
- Iguratimod
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Iguratimod
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Clinical Efficacy of Immunomodulators in RA Patients
NCT05626348 · ClinicalTrials.gov ↗ · Arthritis, Rheumatoid
|
Phase 4 | Recruiting | Qilu Hospital of Shandong University | China |
|
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
NCT06244628 · ClinicalTrials.gov ↗ · cGVHD
|
Phase 1/2 | Recruiting | Xuzhou Medical University | China |
|
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NCT05789030 · ClinicalTrials.gov ↗ · Autoimmune Diseases
|
Not applicable | Recruiting | Peking Union Medical College Hospital | China |
|
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
NCT07057778 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP)
|
Phase 2 | Not yet open | Peking University People's Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Iguratimod
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 1 |
| Qilu Hospital of Shandong University | 1 |
| Xuzhou Medical University | 1 |
| Peking University People's Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Iguratimod trials
How many clinical trials are testing Iguratimod?
4 current trials in our China register name Iguratimod (also registered as T-614) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Iguratimod trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Iguratimod clinical trials?
Peking Union Medical College Hospital (1), Qilu Hospital of Shandong University (1), Xuzhou Medical University (1) and Peking University People's Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Iguratimod works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iguratimod works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iguratimod (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.